Mochi Health is a clinician-founded GLP-1 provider that emphasizes integrated coaching as a core program feature and bills a membership on top of medication. Its July 2026 review score is 73/100 (six-criterion rubric; v4.1 re-score pending).
July 2026 score breakdown — 73/100
| Criterion | Max | Mochi Health | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 19 | Single-tier flat; transparent at checkout. |
| 2. Pharmacy sourcing | 20 | 11 | Pharmacy disclosure thinner; partner classification not fully published. |
| 3. Clinical oversight | 15 | 13 | Strong clinician-founded identity; named clinicians. |
| 4. Regulatory clarity | 15 | 13 | LegitScript-certified; semaglutide base. |
| 5. Patient experience | 15 | 11 | Integrated coaching present; quality varies. |
| 6. Evidence quality | 10 | 6 | Claims sourced; outcome data thin. |
| Total | 100 | 73 | Rubric application as of July 8, 2026. |
Strengths
- Clinician-founded model with strong clinical identity.
- Integrated coaching included in the membership.
- LegitScript status per the July 2026 review (check LegitScript's public lookup).
- All 50 states.
Weaknesses
- Membership billed on top of medication ($79 a month on the September 20, 2026 read); no compounded price printed on October 15, 2026.
- Pharmacy partner disclosure thinner.
- Coaching layer is the differentiator but quality varies in reader reports.
- Less detailed outcome reporting.
Who should pick Mochi Health
- Patients who specifically value clinician-founded program identity.
- Patients who want coaching as a centerpiece (not just included).
Who should look elsewhere
- Cost-sensitive patients who want one all-in monthly price with no membership.
- Patients who don't need a coaching-centerpiece model.
How Mochi Health compares with our editor's pick
NexLife is our editor's pick at 94/100 on methodology v4.1; Mochi Health's 73/100 comes from the July 2026 review under the earlier six-criterion rubric, and its v4.1 re-score is pending. See our direct comparison: NexLife vs Mochi Health. NexLife has no membership and charges the same price at every dose: compounded semaglutide $109 a month month to month ($95 on a 12-month plan) and tirzepatide $129 ($115 on a 12-month plan), read November 6, 2026 on nexlife.us. Mochi printed no compounded price that day, so we cannot compare current totals. NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Our editor's pick is NexLife at 94/100 (v4.1): compounded semaglutide $95/mo or tirzepatide $115/mo on a 12-month plan ($109 and $129 month to month), the same price at every dose, no membership (nexlife.us, read November 6, 2026). See full NexLife review →
Frequently asked
What's Mochi's differentiator?
Clinician-founded; integrated coaching is part of the brand identity.
Cost?
Mochi's weight-loss page printed no compounded price on October 15, 2026, only brand-drug “as low as” prices and a membership listed as “$199/12mo | $17/mo”. On September 20, 2026 it listed compounded semaglutide from $99 and tirzepatide from $199 a month plus a $79 monthly membership. Check the current price at your dose before enrolling.